Earnings Preview: Entrada Therapeutics, Inc. (TRDA) Q4 Earnings Expected to Decline

Core Viewpoint - Entrada Therapeutics, Inc. (TRDA) is anticipated to report a significant year-over-year decline in earnings and revenues for the quarter ended December 2025, which could impact its stock price depending on the actual results compared to estimates [1][3]. Earnings Expectations - The consensus estimate indicates a quarterly loss of $1.32 per share, reflecting a drastic year-over-year change of -4500% [3]. - Expected revenues are projected at $1.29 million, down 96.6% from the same quarter last year [3]. Estimate Revisions - Over the last 30 days, the consensus EPS estimate has been revised down by 1.52%, indicating a reassessment by analysts regarding the company's earnings prospects [4]. - The Most Accurate Estimate for Entrada Therapeutics is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -59.09%, suggesting a bearish outlook from analysts [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive or negative reading can predict the deviation of actual earnings from consensus estimates, but it is more reliable for positive readings [9][10]. - The current Zacks Rank for Entrada Therapeutics is 3, which complicates the prediction of an earnings beat [12]. Historical Performance - In the last reported quarter, Entrada Therapeutics was expected to post a loss of $1.04 per share but actually reported a loss of -$1.06, resulting in a surprise of -1.92% [13]. - Over the past four quarters, the company has beaten consensus EPS estimates twice [14]. Conclusion - Overall, Entrada Therapeutics does not appear to be a strong candidate for an earnings beat, and investors should consider other factors before making investment decisions [17].